POS-144 A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, PARALLEL GROUP SAFETY AND BIOAVAILABILITY STUDY OF BION-1301 ADMINISTERED BY INTRAVENOUS (IV) AND SUBCUTANEOUS (SC) ROUTES

• C. SIBLEY,
• A. Mittan,
• A. Endsley,
• S. Roy,
• J. Lee,
• S. Lewis,
• J. Lo,
• A. Glicklich

Affiliations

C. SIBLEY

Chinook Therapeutics Inc., Clinical Development, Seattle, Washington, United States

A. Mittan

Chinook Therapeutics Inc., Clinical Operations, Seattle, Washington, United States

A. Endsley

Certara, PK/PD Modeling, Princeton, New Jersey, United States

S. Roy

Chinook Therapeutics Inc., Project Leadership, Seattle, Washington, United States

J. Lee

Chinook Therapeutics Inc., Clinical Operations, Seattle, Washington, United States

S. Lewis

Chinook Therapeutics Inc., Biometrics, Seattle, Washington, United States

J. Lo

Chinook Therapeutics Inc., Translational Medicine, Seattle, Washington, United States

A. Glicklich

Chinook Therapeutics Inc., Clinical Development, Seattle, Washington, United States